High doses of Vitamin D3 increases LL37 peptide. It's the best activator of this peptide. It basically punches holes in bacteria cells so it's a broad spectrum antibiotic that is part of our innate immune system. at least 5000IU a day of D3 would increase expression of LL37. High doses can be used for shorter periods like 150,000IU a day for a few days then you can reduce to a lower dose of 5000. I've done this a few times and noticed that it increases my symptoms (wasn't on antibiotics at the time). Though while taking antibiotics it could be a good thing.
two other points I wanted to share:
Doxycycline suppresses the immune system upon each dose. I remembered something; Beta glucan (I've used Now beta-1,3/1,6-D-Glucan) is a powerful activator of the immune system. Beta glucan combined with antibiotics (google this to research) can reduce the amount of antibiotic needed to kill bacteria by HALF. Lots of abstracts to studies here:
https://www.beta-glucan-13d.com/images/infectious.pdf
also heres a study I just found of how effective combining antibiotics plus glucan is.
https://www.partnec.com/rd/rdgf/3/pdf22.pdf
"These findings lead to the idea
that immunotherapy using the D-fraction in combination
with antibiotics restores the damaged immune and bactericidal
functions of high-risk group patients and reduced the
dosage of VCM, effective for not only MRSA, but also
secondary infection including Lysteriosis"
Also doxycycline inhibits nitric oxide, which L-arginine increases. Nitric oxide is used to kill bacteria.
Human host defense peptide LL-37 prevents bacterial biofilm
formation.
Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, Hancock RE.
Centre for Microbial Diseases & Immunity Research, University of
British Columbia, Vancouver, British Columbia, Canada.
The ability to form biofilms is a critical factor in chronic
infections by Pseudomonas aeruginosa and has made this bacterium a
model organism with respect to biofilm formation. This study describes
a new, previously unrecognized role for the human cationic host
defense peptide LL-37. In addition to its key role in modulating the
innate immune response and weak antimicrobial activity, LL-37 potently
inhibited the formation of bacterial biofilms in vitro. This occurred
at the very low and physiologically meaningful concentration of 0.5
microg/ml, far below that required to kill or inhibit growth (MIC = 64
microg/ml). LL-37 also affected existing, pregrown P. aeruginosa
biofilms. Similar results were obtained using the bovine neutrophil
peptide indolicidin, but no inhibitory effect on biofilm formation was
detected using subinhibitory concentrations of the mouse peptide
CRAMP, which shares 67% identity with LL-37, polymyxin B, or the
bovine bactenecin homolog Bac2A. Using microarrays and follow-up
studies, we were able to demonstrate that LL-37 affected biofilm
formation by decreasing the attachment of bacterial cells, stimulating
twitching motility, and influencing two major quorum sensing systems
(Las and Rhl), leading to the downregulation of genes essential for
biofilm development.